SCHEMBL2290547

SCHEMBL2290547

C1=CC2C(=C1)C=Cc1ccccc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 2/20 0.39
HTR6 P50406 1/20 0.35
KDM4E B2RXH2 2/20 0.33
CYP2D6 P10635 2/20 0.33
LMNA P02545 1/20 0.33
TP53 P04637 1/20 0.33
CHRM2 P08172 1/20 0.33
CYP3A4 P08684 1/20 0.33
CHRM1 P11229 1/20 0.33
DRD2 P14416 1/20 0.33
ADRA2B P18089 1/20 0.33
ADRA2C P18825 1/20 0.33
NFKB1 P19838 1/20 0.33
CHRM3 P20309 1/20 0.33
SLC6A2 P23975 1/20 0.33
HTR2C P28335 1/20 0.33
ADRA1A P35348 1/20 0.33
HRH1 P35367 1/20 0.33
DRD3 P35462 1/20 0.33
THPO P40225 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11884483 0.92 HTR2A (0.37) HTR2AHTR6KDM4ECYP2D6LMNA
SCHEMBL6204566 0.83 HTR2A (0.33) HTR2AHTR6
SCHEMBL9806274 0.78
SCHEMBL3239448 0.74 HTR2A (0.45) HTR2AHTR6KDM4ECYP2D6LMNA
SCHEMBL1664032 0.72 HTR6 (0.32) HTR2AHTR6
SCHEMBL6633705 0.71 TBXA2R (0.36) KDM4ETP53MEN1KMT2A
SCHEMBL27817134 0.71 HTR6 (0.31) HTR2AHTR6
SCHEMBL8330852 0.69 HTR2A (0.36) HTR2AHTR6KDM4ECYP2D6LMNA
SCHEMBL6195775 0.68 SHBG (0.32)
SCHEMBL28839808 0.68 HTR2A (0.34) HTR2AHTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11040995-B2 Catalyst comprising a metallocene complex and co-catalyst SABIC GLOBAL TECHNOLOGIES B.V. (NL) 2021-06-22 US claimed
US-20200270292-A1 CATALYST COMPRISING A METALLOCENE COMPLEX AND CO-CATALYST SABIC GLOBAL TECHNOLOGIES B.V. (NL) 2020-08-27 US claimed
EP-3400230-B1 CATALYST COMPRISING A METALLOCENE COMPLEX AND A CO-CATALYST SABIC GLOBAL TECHNOLOGIES BV (NL) 2019-09-11 EP claimed
EP-3400230-A1 CATALYST COMPRISING A METALLOCENE COMPLEX AND A CO-CATALYST SABIC Global Technologies B.V. (NL) 2018-11-14 EP claimed
WO-2017118617-A1 CATALYST COMPRISING A METALLOCENE COMPLEX AND A CO-CATALYST SABIC GLOBAL TECHNOLOGIES B.V. (NL) 2017-07-13 WO claimed
US-7575785-B2 use thereof in liquid-crystalline media, and and to electro-optical display elements containing these liquid-crystalline media; negative dielectric anisotropy MERCK PATENT GMBH (DE) 2009-08-18 US claimed
US-20060202163-A1 Cyclopenta[a]naphthaline derivatives MERCK PATENT GMBH (DE) 2006-09-14 US claimed
US-20250223285-A1 NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS JACOBIO PHARMACEUTICALS CO LTD (CN) 2025-07-10 US disclosed
US-11339230-B2 Transition metal compound, catalyst composition including the same, and method for preparing ethylene homopolymer or copolymer of ethylene and α-olefin using the same SABIC SK NEXLENE COMPANY PTE. LTD. (SG) 2022-05-24 US disclosed
US-11339230-B2 Transition metal compound, catalyst composition including the same, and method for preparing ethylene homopolymer or copolymer of ethylene and α-olefin using the same SABIC SK NEXLENE COMPANY PTE. LTD. (SG) 2022-05-24 US disclosed
US-11040995-B2 Catalyst comprising a metallocene complex and co-catalyst SABIC GLOBAL TECHNOLOGIES B.V. (NL) 2021-06-22 US disclosed
US-20210139617-A1 NOVEL TRANSITION METAL COMPOUND, CATALYST COMPOSITION INCLUDING THE SAME, AND METHOD FOR PREPARING ETHYLENE HOMOPOLYMER OR COPOLYMER OF ETHYLENE AND ALPHA-OLEFIN USING THE SAME SABIC SK NEXLENE COMPANY PTE. LTD. (SG) 2021-05-13 US disclosed
US-20210139617-A1 NOVEL TRANSITION METAL COMPOUND, CATALYST COMPOSITION INCLUDING THE SAME, AND METHOD FOR PREPARING ETHYLENE HOMOPOLYMER OR COPOLYMER OF ETHYLENE AND ALPHA-OLEFIN USING THE SAME SABIC SK NEXLENE COMPANY PTE. LTD. (SG) 2021-05-13 US disclosed
US-6737125-B2 SUCH AS 8,9-DIFLUORO-7-(4-PENTYLPHENYL)-2-PROPYL-2,3-DIHYDRO-1H -CYCLOPENTA(A)NAPHTHALENE; FOR USE IN AUTOMOBILE INTERIORS CLARIANT FINANCE (BVI) LIMITED (VG) 2004-05-18 US disclosed
US-6737125-B2 SUCH AS 8,9-DIFLUORO-7-(4-PENTYLPHENYL)-2-PROPYL-2,3-DIHYDRO-1H -CYCLOPENTA(A)NAPHTHALENE; FOR USE IN AUTOMOBILE INTERIORS CLARIANT FINANCE (BVI) LIMITED (VG) 2004-05-18 US disclosed
US-6706707-B2 TREATMENT OR PREVENTION OF MGLUR5 RECEPTOR MEDIATED DISORDERS. HOFFMAN-LA ROCHE INC. 2004-03-16 US disclosed
US-20030108684-A1 Such as 8,9-difluoro-7-(4-pentylphenyl)-2-propyl-2,3-dihydro-1H -cyclopenta(a)naphthalene; for use in automobile interiors CLARIANT INTERNATIONAL LTD. 2003-06-12 US disclosed
US-20030108684-A1 Such as 8,9-difluoro-7-(4-pentylphenyl)-2-propyl-2,3-dihydro-1H -cyclopenta(a)naphthalene; for use in automobile interiors CLARIANT INTERNATIONAL LTD. 2003-06-12 US disclosed
EP-1129090-A1 PENTAAZA-CYCLOPENTA A]NAPHTHALENE DERIVATIVES AS LIGANDS FOR GABA A? $g(a)5 RECEPTORS MERCK SHARP & DOHME LTD. (GB) 2001-09-05 EP disclosed
WO-2000029412-A1 PENTAAZA-CYCLOPENTA[A]NAPHTHALENE DERIVATIVES AS LIGANDS FOR GABAA α5 RECEPTORS MERCK SHARP & DOHME LIMITED (GB) 2000-05-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030108684-A1 Such as 8,9-difluoro-7-(4-pentylphenyl)-2-propyl-2,3-dihydro-1H -cyclopenta(a)naphthalene; for use in automobile interiors SCO2, CYP2F1, OGFOD1 HTR2A 3721/4885HTR6 4492/4885KDM4E 3867/4885
US-20210139617-A1 NOVEL TRANSITION METAL COMPOUND, CATALYST COMPOSITION INCLUDING THE SAME, AND METHOD FOR PREPARING ETHYLENE HOMOPOLYMER OR COPOLYMER OF ETHYLENE AND ALPHA-OLEFIN USING THE SAME NOTUM, ALOX12, ETFA HTR2A 4375/4885HTR6 4036/4885KDM4E 3020/4885
US-20250223285-A1 NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS PTPN5, PTPN1, PTPRJ HTR2A 3938/4885HTR6 4326/4885KDM4E 1233/4885
US-20060202163-A1 Cyclopenta[a]naphthaline derivatives XPA, XDH, NUCB2 HTR2A 1814/4885HTR6 4375/4885KDM4E 4506/4885
US-11339230-B2 Transition metal compound, catalyst composition including the same, and method for preparing ethylene homopolymer or copolymer of ethylene and α-olefin using the same NOTUM, ALOX12, ETV6 HTR2A 4415/4885HTR6 3886/4885KDM4E 3142/4885
US-11040995-B2 Catalyst comprising a metallocene complex and co-catalyst CCRL2, UBE2L3, MAL2 HTR2A 3350/4885HTR6 3212/4885KDM4E 1016/4885
US-20200270292-A1 CATALYST COMPRISING A METALLOCENE COMPLEX AND CO-CATALYST LAS1L, CCNE2, CKS2 HTR2A 3283/4885HTR6 2843/4885KDM4E 517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.